Table 3.
ORR and DCR in different subgroups.
| Subgroup | ORR (%) | DCR (%) |
|---|---|---|
| Metastatic sites | ||
| Lymph nodes (n = 614) | 39.3 | 77.2 |
| Bone (n = 401) | 34.9 | 74.6 |
| Lung (n = 493) | 33.7 | 76.1 |
| Liver (n = 363) | 31.1 | 68.6 |
| Brain (n = 47) | 17.0 | 76.6 |
| Number of metastasis | ||
| 1 (n = 189) | 46.0 | 84.1 |
| 2 (n = 329) | 36.8 | 74.5 |
| ⩾3 (n = 481) | 33.5 | 75.3 |
| ECOG performance status | ||
| 0 (n = 275) | 33.8 | 75.3 |
| 1 (n = 699) | 38.1 | 78.0 |
| 2 (n = 29) | 24.1 | 69.0 |
| Disease status | ||
| Unresectable locally advanced (n = 205) | 48.3 | 82.9 |
| Recurrent/metastatic (n = 818) | 33.9 | 75.6 |
| Molecular subtype | ||
| HR positive, HER2 negative (n = 302) | 36.4 | 79.8 |
| HER2-positive (n = 376) | 37.0 | 74.2 |
| Triple negative (n = 211) | 36.5 | 74.9 |
| Menopause | ||
| No (n = 384) | 39.6 | 77.1 |
| Yes (n = 623) | 34.7 | 77.0 |
| Age (years) | ||
| <65 (n = 957) | 36.5 | 76.5 |
| ⩾65 (n = 56) | 39.3 | 83.9 |
| Chemotherapy regimens | ||
| LBP alone (n = 52) | 26.9 | 63.5 |
| LBP + paclitaxel (n = 125) | 49.6 | 85.6 |
| LBP + docetaxel (n = 240) | 51.7 | 84.6 |
| LBP + gemcitabine (n = 201) | 29.4 | 72.1 |
| LBP + vinorelbine (n = 342) | 28.9 | 76.3 |
DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LBP, lobaplatin; ORR, objective response rate.